Neprilysin (neutral endopeptidase, NEP) is a cell surface peptidase whose expression is lost in approximately 50% of prostate cancers (PC). NEP normally functions to inactivate peptides such as bombesin and endothelin-1, and potentiates the effects of the PTEN tumor suppressor via a direct protein-protein interaction. NEP loss contributes to PC progression. We investigated the therapeutic efficacy of using a lentiviral vector system to restore NEP expression in PC cells. These experiments demonstrate that lentiviral NEP gene transfer is a novel targeted strategy for the treatment of NEP-deficient PC.
Introduction
Prostate cancer (PC) is the most frequently diagnosed malignancy in men in the United States. 1 Advances in surgery, radiation therapy, hormonal therapy and chemotherapy have resulted in improved survival for patients with all stages of PC. Nevertheless, approximately 30 000 men die each year from this disease, highlighting the need to develop novel therapies to treat advanced PC. An increased understanding of the molecular abnormalities that contribute to PC progression will lead to the development of more effective targeted treatments based on this knowledge.
One abnormality identified in B50% of PCs is loss of expression (via hypermethylation or androgen withdrawal) of the tumor suppressor protein neprilysin (neutral endopeptidase, NEP, CD10). [2] [3] [4] NEP is a 90-110-kDa cell surface peptidase normally expressed on prostatic epithelial cells. NEP functions to catalytically inactivate a variety of peptides that contribute to PC progression, including endothelin-1, bombesin and basic fibroblast growth factor (FGF-2). 5, 6 Through its enzymatic function, NEP inhibits neuropeptide-mediated PC cell growth, cell migration, focal adhesion kinase (FAK) phosphorylation, Akt phosphorylation and FGF-2-mediated angiogenesis. [5] [6] [7] NEP protein also directly interacts with ezrin/radixin/moesin (ERM) proteins resulting in decreased binding of ERM proteins to the hyaluronan receptor CD44 such that cells expressing NEP demonstrate decreased cell adhesion and cell migration. 8 Moreover, NEP directly binds the phosphatase and tensin homologue (PTEN) tumor suppressor protein, recruiting endogenous PTEN to the cell membrane, leading to prolonged PTEN protein stability and increased PTEN phosphatase activity, and resulting in a constitutive downregulation of Akt activity. 9 Finally, overexpression of NEP using a tetracycline repressive system inhibits tumorigenicity in an orthotopic PC model. 10 These antitumor activities of the NEP protein suggest that reintroduction of NEP using gene transfer into NEPdeficient PC may be a viable antitumor strategy for locally recurrent PC.
Lentiviruses have been used as gene transfer vectors for over 10 years in a variety of applications with the advantage that they efficiently integrate into the genome of nondividing cells, providing stable transgene expression. Recent studies have begun to examine their utility in cancer gene therapy. Pellinen et al. reported a 50-95% lentiviral gene transfer efficiency in studies of 42 tumor cell lines from 10 different human tumor types. 12 More importantly, lentiviral-mediated inhibition of cell growth and/or tumor formation in athymic mice have been demonstrated in PC, [13] [14] [15] [16] liver cancer, 17 oral squamous cancer, 18 cervical cancer 19 and melanoma. 17, 20 In the current study, we examined the feasibility and antitumor effects of using a lentiviral vector to express NEP in NEPdeficient PC cells.
Materials and methods

Cells and reagents
22RV1 human PC cells (ATCC, Manassas, VA) were grown in RPMI 1640 medium supplemented with 2 mM glutamine, 1% nonessential amino acids, 100 units/ml streptomycin and penicillin, and 10% fetal calf serum (FCS). Antibodies used in this study include anti-NEP antibody (NCL-CD10-270, Novocastra Laboratories Ltd, Newcastle upon Tyne, UK), anti-phospho-Akt antibody (Ser473, Cell Signaling Technology, Inc., Beverly, MA), anti-Akt antibody (Cell Signaling Technology, Inc.), antiphospho-FAK antibody (Tyr397, Biosource, Camarillo, CA), anti-FAK antibody (C-20, Santa Cruz Biotechnology, Inc., Santa Cruz, CA), anti-PTEN antibody (A2B1, Santa Cruz Biotechnology, Inc.), anti-green fluorescent protein (anti-GFP) antibody (B-2, Santa Cruz Biotechnology, Inc.) and anti-b-actin antibody (Sigma-Aldrich, St Louis, MO).
Lentiviral vector production and transduction
A four-plasmid expression system was used to generate third-generation lentiviral vectors by transient transfection as described previously. 21, 22 The vector plasmids that expressed L-GFP and wild-type NEP (L-NEP) driven by the human cytomegalovirus promoter were constructed as described. 21, 22 The lentiviral vector titers were estimated by flow cytometric analyses (FACS) as described. 21 Cells were transduced with L-GFP or L-NEP at the indicated multiplicity of infection (MOI) in the presence of 6 mg/ml polybrene (Sigma-Aldrich) for 48-72 h and used for the following experiments.
NEP enzyme activity assay NEP-specific enzyme activities in the transduced cells and tissues were assessed as described previously using SucAla-Ala-Phe-pNA (Bachem Bioscience Inc., Philadelphia, PA) as substrate. 23 Specific activities were expressed as picomoles per milligram of protein per minute and represent the mean of three separate measurements performed on three independent infection experiments.
Cell counts and cell viability assays
Following incubation overnight in six-well plates (1 Â 104 cells/well in triplicate), cells were infected with L-GFP or L-NEP at the indicated MOI. Total cell numbers in three independent wells in each group were counted at the indicated time after infection using a hemocytometer, and the mean value of four fields was recorded. The results were expressed as mean7s.e. of total cell numbers in each well in each group. Cell viability was assessed by a 3-(4,5-dimethylthiazol-2-yl)-5-3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS) assay using Cell Titer96 Aqueous kit (Promega, Madison, WI) according to the manufacturer's recommendation. Briefly, cells were incubated overnight in 96-well plates (5 Â 10 3 cells/well) and then infected with L-GFP or L-NEP at the indicated MOI for 72 h. Two hours after adding MTS, the plates were read in a microplate autoreader at a wavelength of 490 nm. The results were expressed as the mean optical density (OD) of the six-well set for each group and repeated two times with similar results.
Immunoblotting
Total cell lysate preparation and immunoblotting was performed as described. 7, 9 Proteins were visualized using enhanced chemiluminescence (Amersham Biosciences) according to the manufacturer's recommendations.
Matrigel invasion assay
Invasion was assessed by the counting of the cells that migrated across 8-mm pore Matrigel-coated transwell inserts (BD Biosciences, San Jose, CA) as described. 24 Briefly, cells infected with L-GFP or L-NEP at MOI 10 for 48 h were trypsinized, and a cell suspension of 2 Â 10 5 cells in 500 ml of serum-free medium was added to the insert and 750 ml of medium containing 10% FCS was added to the lower chamber. Following incubation for 24 h at 371C, membranes were fixed and stained using Diff-Quik Stain Set (Dade Behring, Inc., Deerfield, IL), and the numbers of invaded cells were determined at 40-fold magnification in at least 10 fields of each well. Results represent mean of one experiment performed in triplicate.
Xenograft model
Semi-confluent uninfected 22RV1 cells were trypsinized and suspended in Matrigel (5 Â 10 6 cells per 100 ml) and then inoculated subcutaneously into the flank of athymic male mice (Taconic, Hudson, NY). When the average tumor diameter reached 5 mm, mice were randomly divided into two groups (n ¼ 8 per cohort). Tumors were injected one time with L-GFP or L-NEP (5 Â 10 8 pfu in 100 ml) at 4-5 different sites. The size of each tumor was monitored every 3 or 4 days. The tumor volume (mm 3 ) was estimated by using the formula: tumor volume ¼ width 2 Â length Â 0.52. 16 All mice were killed on day 30 after viral injection, and the tumors were removed and weighed. Sections of each tumor were formalin fixed and paraffin embedded. Animal experimentation was reviewed and approved by the Weill Cornell Institutional Animal Care and Use Committee.
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Immunostaining of NEP Paraffin-embedded tissue sections were stained with anti-NEP antibody (NCL) at 1:80 dilution using the DAKO Envision þ System HRP (DakoCytomation, Carpinteria, CA) according to the manufacturer's instructions.
Statistical analysis
All analyses were done using Statview 5.0 (SAS Institute, Inc., Cary, NC). Results were expressed as the mean7s.e. for three independent measurements. analysis of variance was used for analyses of continuous data followed by Fisher's protected least significant difference for post hoc analyses. Differences with a Po0.05 were determined as statistically significant.
Results
Lentiviral transduction of L-NEP and GFP
The 22RV1 cell line is a castrate-resistant derivative of the androgen-sensitive CWR22 parental tumor, which grows in tissue culture and as a xenograft in athymic mice. 25 Catalytically active NEP (B200 pmol/mg/min) is present in CWR22 xenografts, which decreases within 10 days of castrating the host animal, 3 and is present at low levels in 22RV1 cells or tumors. 22RV1 cells infected with L-NEP or L-GFP at MOIs ranging from 0.1 to 10 for 72 h were lysed and total cell lysates were analyzed for NEP protein expression by immunoblotting. As shown in Figure 1a Expression of NEP in wild-type-5 (WT-5) cells using a tetracycline repressible expression system has previously been shown to result in decreased FAK phosphorylation, Akt phosphorylation and increased PTEN expression. 7, 9 We therefore next assessed whether lentiviral-transduced NEP would have similar effects on 22RV1 cells. As shown in Figure 3 
Discussion
Expression of NEP is transcriptionally activated by androgen in androgen-dependent PC cells and decreases with androgen withdrawal. 2 Consequently, PC cells that survive androgen withdrawal can emerge with reduced levels of NEP.
2 Consistent with this observation, castration of mice implanted with androgen-dependent CWR22 tumor leads to a progressive decline in tumor NEP enzyme activity over 10 days, whereas the CWR22R castrate-resistant PC subline that regrows lacks NEP expression. 3 This decrease in NEP expression contributes Our previous studies demonstrate the potential of using NEP as an antitumor agent against castrate-resistant PC. Recombinant NEP (rNEP) inhibits PC cell growth in vitro, 2 and overexpression of NEP using a tetracycline repressible system inhibits WT-5 cell growth within the mouse prostate in an orthotopic PC model. 10 However, daily intraperitoneal administration of rNEP did not inhibit growth of PC xenografts in athymic mice, possibly because of the inability to achieve sufficient NEP serum concentrations using systemically administered rNEP. 10 Therefore, to obtain high and sustained local concentrations of NEP at or near PC cells, we used lentiviral vectors to transduce NEP into NEP-deficient 22RV1 cells.
Lentiviral vectors have many advantages for gene therapy, including the ability to infect nondividing cells, long-term transgene expression and absence of induction of an inflammatory and immune response. 22 Lentiviral NEP gene transfer was first developed as a therapeutic tool to treat Alzheimer's Disease. NEP is a major amyloid beta peptide-degrading enzyme and intracerebral injection of NEP-expressing lentivirus results in a B50% reduction in the number of amyloid plaques. 21, 26 In the present study, we show that high NEP protein levels can be achieved in PC cells using the same lentiviral NEP vector system. The level of NEP-specific enzymatic activity in transduced 22RV1 cells (41000 pmol/mg/min) was similar to that achieved in our prior studies using WT-5 cells 2, 7, 10 and similarly resulted in significant growth inhibition in vitro and tumor inhibition in vivo.
NEP has numerous antitumor effects mediated by catalytic action on NEP substrates and by direct and indirect protein interactions with other intracytoplasmic proteins involved in regulating cell growth, cell motility and cell survival. Similar to our prior studies using rNEP and induced expression of cell surface NEP, lentiviraltransduced NEP inhibited cell viability, proliferation and invasion. Moreover, Akt and FAK phosphorylation were significantly inhibited and PTEN protein expression increased as NEP prolongs the half-life of the PTEN protein. 9 Thus, lentiviral NEP gene transfer appears as an effective strategy to express biologically active NEP in PC cells.
In suggesting that an uninfected cell population may develop following a single intratumor dose and repeated injections may be needed to achieve tumor eradication. As we previously demonstrated that NEP significantly potentiates chemotherapy effectiveness in PC cells, 27 a therapeutic approach could combine lentiviral NEP with systemic chemotherapy.
In summary, lentiviral gene transfer is an effective means of delivering NEP to PC cells and results in marked suppression of tumor growth, suggesting that NEP is potentially a novel therapeutic strategy to target NEPdeficient PC cells. One limitation of this approach in humans is the need to directly inject lentivirus into PC cells. Recent studies indicate that use of the prostatespecific antigen (PSA) enhancer core element can confer tissue-specific expression of a lentiviral vector. 28 This suggests that intravenous administration of L-NEP may represent an alternative approach to target NEP to PC cells as has been reported using another PSA promoterbased lentiviral vector to deliver diptheria toxin A to LNCaP cells. 16 Future studies will define the utility of NEP gene therapy in PC.
